The NSCLC RET fusion-positive cohort had a significantly lower number of TMB-H cases and median TMB when compared to the NSCLC RET fusion-negative cohort (P < 0.001; Table 2). The gene discussed is RET; the disease is non-small cell lung carcinoma.